{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:50:05Z","timestamp":1761587405419,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.109042","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:05:37Z","timestamp":1657803937000},"page":"109042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["C5a receptor antagonism coming of age for vascular pathology"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-6083","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Marceau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Petitclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2022","key":"10.1016\/j.intimp.2022.109042_b0005","first-page":"83","article-title":"FDA approvals","volume":"21","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2022.109042_b0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"issue":"2-3","key":"10.1016\/j.intimp.2022.109042_b0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01893020","article-title":"Structure and function of the anaphylatoxins","volume":"7","author":"Hugh","year":"1984","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.intimp.2022.109042_b0020","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1016\/S0021-9258(17)38013-4","article-title":"Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a","volume":"253","author":"Fernandez","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2022.109042_b0025","doi-asserted-by":"crossref","unstructured":"A. Klos, E. Wende, K.J. Wareham, P.N. Monk. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65 (2013) 500-543.","DOI":"10.1124\/pr.111.005223"},{"key":"10.1016\/j.intimp.2022.109042_b0030","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","article-title":"The complement receptor C5aR2: A powerful modulator of innate and adaptive immunity","volume":"202","author":"Li","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109042_b0035","doi-asserted-by":"crossref","unstructured":"A. Cianciulli, L. Coulthard, O. Hawksworth, J.D. Lee, X.X. Li, V. Mitolo V, et al. Complement peptide receptors in GtoPdb v.2021.3. IUPHAR\/BPS Guide to Pharmacology. DOI: 10.2218\/gtopdb\/F5\/2021.3.","DOI":"10.2218\/gtopdb\/F5\/2021.3"},{"key":"10.1016\/j.intimp.2022.109042_b0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF01965121","article-title":"Role of histamine in the spasmogenic effect of the complement peptides C3a and C5a-desArg (classical anaphylatoxin)","volume":"12","author":"Sorgenfrei","year":"1982","journal-title":"Agents Actions"},{"key":"10.1016\/j.intimp.2022.109042_b0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-3565(25)21763-3","article-title":"Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels","volume":"230","author":"Marceau","year":"1984","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2022.109042_b0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1476-5381.1985.tb16155.x","article-title":"Effects of the C5a anaphylatoxin and its relationship to cyclo-oxygenase metabolites in rabbit vascular strips","volume":"84","author":"Hugli","year":"1985","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109042_b0055","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/01.RES.67.5.1059","article-title":"Contractile effect of the chemotactic factors f-Met-Leu-Phe and C5a on the human isolated umbilical artery. Role of cyclooxygenase products and tissue macrophages","volume":"67","author":"Marceau","year":"1990","journal-title":"Circ. Res."},{"key":"10.1016\/j.intimp.2022.109042_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0162-3109(86)90039-1","article-title":"Anaphylatoxin C5a fails to promote prostacyclin release in cultured endothelial cells from human umbilical veins","volume":"12","author":"Lundberg","year":"1986","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.intimp.2022.109042_b0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00005344-200212000-00002","article-title":"Contractile effect of anaphylatoxin C5a and of a mimetic peptide on the human umbilical artery: further evidence for leukocyte-dependent vasomotion","volume":"40","author":"Fortin","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109042_b0070","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0006-2952(96)00513-8","article-title":"Evidence for vascular tone regulation by resident or infiltrating leukocytes","volume":"52","author":"Marceau","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109042_b0075","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.4049\/jimmunol.156.9.3426","article-title":"Pathologic leukocyte infiltration of the rabbit aorta confers a vasomotor effect to chemotactic peptides through cyclooxygenase-derived metabolites","volume":"156","author":"Petitclerc","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109042_b0080","first-page":"471","article-title":"C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes","volume":"128","author":"Lundberg","year":"1987","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2022.109042_b0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0162-3109(87)90031-2","article-title":"Effects of the anaphylatoxins on circulation","volume":"14","author":"Marceau","year":"1987","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.intimp.2022.109042_b0090","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/01.RES.66.4.1103","article-title":"Role of thromboxane A2 in the cardiovascular response to intracoronary C5a","volume":"66","author":"Stahl","year":"1990","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.intimp.2022.109042_b0095","doi-asserted-by":"crossref","first-page":"e0164646","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109042_b0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","article-title":"International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences","volume":"57","author":"Leeb-Lundberg","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2022.109042_b0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000467889","article-title":"Biochemistry and biology of anaphylatoxins","volume":"3","author":"Hugli","year":"1986","journal-title":"Complement"},{"key":"10.1016\/j.intimp.2022.109042_b0110","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.4049\/jimmunol.148.10.3165","article-title":"Biologic activity of synthetic analogues of C5a anaphylatoxin","volume":"148","author":"Ember","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109042_b0115","article-title":"Hexapeptide analogues of C5a anaphylatoxin reveal heterogeneous neutrophil agonism\/antagonism","volume":"6","author":"Mollison","year":"1992","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2022.109042_b0120","doi-asserted-by":"crossref","unstructured":"G. Drapeau, S. Brochu, D. Godin, L. Levesque, F. Rioux, F. Marceau F. Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem. Pharmacol. 45 (1993) 1289-1299.","DOI":"10.1016\/0006-2952(93)90282-2"},{"key":"10.1016\/j.intimp.2022.109042_b0125","doi-asserted-by":"crossref","unstructured":"Z.D. Konteatis, S.J. Siciliano, G. Van Riper, C.J. Molineaux, S. Pandya, P. Fischer P, et al. Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol. 153 (1994) 4200-4205.","DOI":"10.4049\/jimmunol.153.9.4200"},{"key":"10.1016\/j.intimp.2022.109042_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114156","article-title":"Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function","volume":"180","author":"Li","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109042_b0135","doi-asserted-by":"crossref","unstructured":"N.J. Paczkowski, A.M. Finch, J.B. Whitmore, A.J. Short, A.K. Wong AK, P.N. Monk PN, et al. Pharmacological characterization of antagonists of the C5a receptor. Br. J. Pharmacol. 128 (1999) 1461-1466.","DOI":"10.1038\/sj.bjp.0702938"},{"key":"10.1016\/j.intimp.2022.109042_b0140","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41594-018-0067-z","article-title":"Orthosteric and allosteric action of the C5a receptor antagonists","volume":"25","author":"Liu","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109042_b0145","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2022.109042_b0150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/383086a0","article-title":"The C5a chemoattractant receptor mediates mucosal defence to infection","volume":"383","author":"H\u00f6pken","year":"1996","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.intimp.2022.109042_b0155","doi-asserted-by":"crossref","first-page":"e0189017","DOI":"10.1371\/journal.pone.0189017","article-title":"C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid","volume":"12","author":"Hornum","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109042_b0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"27","author":"Kitching","year":"2020","journal-title":"ANCA-associated vasculitis. Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2022.109042_b0165","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood.V76.8.1631.1631","article-title":"Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself","volume":"76","author":"Schindler","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109042_b0170","first-page":"257","article-title":"Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels","volume":"3","author":"Hutchings","year":"2020","journal-title":"Antib. Ther."},{"key":"10.1016\/j.intimp.2022.109042_b0175","doi-asserted-by":"crossref","unstructured":"E.J. Giamarellos-Bourboulis, M. Argyropoulou, T. Kanni, T. Spyridopoulos, I. Otto, O. Zenker O, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br. J. Dermatol. 183 (2020) 176-178.","DOI":"10.1111\/bjd.18877"},{"issue":"6","key":"10.1016\/j.intimp.2022.109042_b0180","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109042_b0185","article-title":"Age and interleukin-15 levels are independently associated with intima-media thickness in obesity-related NAFLD patients","volume":"21","author":"Tarantino","year":"2021","journal-title":"Front. Med. (Lausanne)."},{"key":"10.1016\/j.intimp.2022.109042_b0190","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/07853890.2013.770333","article-title":"Inhibition of the mTOR pathway: a possible protective role in coronary artery disease","volume":"45","author":"Tarantino","year":"2013","journal-title":"Ann. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922005264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:18Z","timestamp":1761587178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922005264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"alternative-id":["S1567576922005264"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109042","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C5a receptor antagonism coming of age for vascular pathology","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109042"}}